Global Infectious Vaccines Partnering Terms and Agreements 2012 to 2018: Updated Deal Trends, Players and Financials - ResearchAndMarkets.com
Sep. 13, 2018
DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The "Global Infectious Vaccines Partnering Terms and Agreements 2012 to 2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Infectious Vaccines Partnering Terms and Agreements 2012 to 2018: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors' vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2012, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Available deals are listed by:Company A-Z Headline value Stage of development at signing Deal component type Specific infectious therapy target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Infectious Vaccines dealmaking
Chapter 3 - Leading Infectious Vaccines deals
Chapter 4 - Most active Infectious Vaccines dealmakers
Chapter 5 - Infectious Vaccines contracts dealmaking directory
Chapter 6 - Infectious Vaccines dealmaking by technology type
Chapter 7 - Partnering resource centerFor more information about this report visit https://www.researchandmarkets.com/research/g67gzf/global_infectious?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180913005996/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/13/2018 03:18 PM/DISC: 09/13/2018 03:18 PM